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Objective: This prospective, randomized, clinical study was undertaken to 
determine whether glucose-insulin-potassium solutions would benefit pa- 
tients undergoing coronary artery bypass grafting because of unstable 
angina. Methods: The study group consisted of 30 patients with unstable 
angina who required coronary artery bypass grafting. In 15 patients, 
glucose-insulin-potassium solution (30% dextrose in water; K ÷, 80 mEq/L; 
regular insulin, 50 units) was given intravenously at 1 ml/kg per hour after 
induction of anesthesia and administration continued for 12 hours after 
aortic unclamping. Fifteen patients in a separate group received 5% 
dextrose in water intravenously at 50 ml/hr. Results: Patients treated with 
glucose-insulin-potassium solution had higher cardiac indices (2.8 -- 0.1 vs 
2.0 -+ 1 L/min per square meter; p < 0.001), lower inotrope scores (0.06 -+ 
0.01 vs 0.46 --- 0.19;p = 0.041), and less weight gain (6.4 -- 9 vs 11.6 -- 1.1 
pounds; p < 0.001) and had shorter times of ventilator support (8.3 -- 0.6 
vs 14.2 -- 0.2 hours; p = 0.003). They had a significantly lower incidence of 
atrial fibrillation (13.3% vs 53.3%; p = 0.020) and had shorter stays in the 
intensive care unit (14.8 -- 1.3 vs 31.6 --+ 5.2 hours; p = 0.002) and in the 
hospital (6.0 - 0.4 vs 8.0 -- 0.7 days; p = 0.010). Conclusions: We conclude 
that glucose-insulin-potassium therapy enhances myocardial performance 
and results in faster recovery from urgent coronary artery bypass grafting. 
(J Thorac Cardiovasc Surg 1997;113:354-62) 
A lthough the operative morbidity and mortality rates for elective coronary artery bypass grafting 
(CABG) have remained stable, urgent and emer- 
gency CABG for unstable angina continues to result 
in higher rates of mortality and morbidity. 1 The 
increased ischemic myocardial damage seen in these 
patients results in decreased ventricular function, 
increased fluid retention, prolonged mechanical 
ventilation and pulmonary dysfunction, and a higher 
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incidence of arrhythmia, all of which contribute to 
longer hospitalizations and increased medical costs. 
Substrate nhancement with glucose is an inter- 
vention that may limit myocardial necrosis during 
urgent surgical revascularization. Although free 
fatty acids are the main energy source for the 
nonischemic myocardium, glucose is a more favor- 
able energy source during periods of ischemia and 
reperfusion and in chronically dysfunctional but 
viable myocardium. 2' 3 In 1965, Sodi-Pollaris and 
colleagues 4 used glucose-insulin-potassium (GIK) 
solutions in patients with acutely infarcting myocar- 
dium and found that they limited electrocardio- 
graphic changes. Subsequent studies that used GIK 
solutions during periods of ischemia in experimental 
preparations and in clinical studies involving pa- 
tients with acute myocardial infarctions and after 
cardiac surgical procedures demonstrated that GIK 
solutions enhanced myocardial performance. 5-12 
These favorable results prompted us to perform 
an experimental study in pigs that simulated the 
conditions of urgent surgical revascularization to
determine whether GIK solutions would decrease 
myocardial damage. 13 Animals underwent 90 rain- 
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utes of coronary occlusion followed by 30 minutes of 
cardioplegic arrest and 180 minutes of reperfusion. 
Hearts treated with G IK  solution had a significant 
decrease in the incidence of ventricular arrhythmia, 
less myocardial acidosis, better preservation of wall 
motion, and the lowest areas of tissue necrosis. The 
best protection from ischemic damage was obtained 
when G IK  solution was given before and during the 
period of coronary occlusion, as well as during 
reperfusion. 'These experimental results prompted 
us to investigate the role of G IK  solution during 
CABG in patients with unstable coronary syn- 
dromes. We sought to determine whether G IK  
solution would not only enhance myocardial perfor- 
mance but also result in a faster recovery from 
CABG operation thereby reducing both intensive 
care unit ( ICU) and total hospital stay. 
Methods 
Approval to use GIK solution in human subjects was 
obtained from the Boston University Medical Center 
Institutional ;:eview Board (protocol E3270/A65). An 
informed consent was obtained from each patient en- 
rolled in the study. 
Eligibility and exclusion criteria. Eligibility criteria for 
patients in this study included all patients with unstable 
angina. Unstable angina was defined as the presence of 
angina at rest necessitating intravenous nitroglycerin, in- 
travenous heparin, or intraaortic balloon pump (IABP) 
therapy. Patients with diabetes mellitus, chronic renal 
failure (creatinine level ->2.0 mg/ml), acute renal failure 
(urine output <20 ml/hr × 3), hyperkalemia (K level ->5.5 
mEq/L), or hepatic insufficiency (total bilirubin level ->2.5 
mg/ml; levels of aspartate aminotransferase and alaninc 
aminotransferase > 100 IU) were excluded from the study. 
In addition, patients who required procedures in combi- 
nation with CABG (valve repair/replacement, aneurysm 
repair) were excluded. Patients who could not tolerate the 
GIK infusion because of hyperglycemia (glucose level 
->325 mg/L) or hyperkalemia (K+ level ->5.5 mEq/L) were 
also excluded. 
Study protocol. Patients who met the eligibility criteria 
for this study were randomized to a GIK or no-GIK group 
on the basis of the last digit of their hospital identification 
number. All patients underwent placement of a central 
intravenous catheter in the holding area before induction 
of anesthesia t which time a Swan-Ganz thermodilution 
catheter (Baxter Healthcare Corp., Edwards Division, 
Irvine, Calif.) was inserted along with a radial artery 
catheter. After the central ine and Swan-Ganz catheter 
were inserted, those patients randomized to the GIK arm 
of the study received an infusion at 1 ml/kg per hour of 
GIK solution consisting of a liter bag of 30% dextrose in 
water with 80 mEq of KC1 and 50 units regular insulin. 
The infusion of the GIK solution continued through the 
induction period and the time before cardiopulmonary 
bypass. After cardiopulmonary b pass was initiated, the 
infusion of the GIK solution was stopped. The infusion 
was restarted immediately after aortic unclamping and 
continued for 12 hours. The no-GIK group received 5% 
dextrose in water infused at 50 ml/hr. 
Operative techniques. Standard operative and anes- 
thetic techniques were used in all patients. Anesthesia was 
induced with fentanyl (25 to 50 tx/kg) and pancuronium 
bromide (Pavulon, 0.1 mg/kg). Patients were supported by 
cardiopulmonary b pass by means of an arterial cannula 
in the ascending aorta and a single venous cannula in the 
right atrium. All vessels that had stenoses of 50% or more 
were bypassed. At least one internal thoracic artery was 
used in each patient. Proximal anastomoses were done 
during cardiopulmonary bypass with the heart beating 
followed by the construction of all distal anastomoses 
during one period of ischemic arrest. Myocardial protec- 
tion was achieved by multidose infusions of antegrade 
cold blood cardioplegic solution (4 ° C; K, 28 mEq/L; pH, 
7.6; hematocrit, 20%) supplemented with systemic (32 ° to 
34 ° C) and topical (cold saline solution lavage at 4 ° C) 
hypothermia. 
Parameters measured and data acquisition. Serum 
glucose and potassium levels were measured before infu- 
sion of GIK solution, before the initiation of cardiopul- 
monary bypass, during cardiopulmonary b pass, and every 
4 hours after aortic unclamping for 18 hours. Electrocar- 
diograms were obtained before operation, immediately 
after operation, and on postoperative days 1, 2, 5, and 7. 
The myocardial fraction of creatinine kinase and lactate 
dehydrogenase isoenzyme level were measured immedi- 
ately after operation and at 6 and 24 hours after opera- 
tion. A perioperative myocardial infarction was diagnosed 
either by the appearance of new changes on the electro- 
cardiogram (Q waves, ST segment elevation ->1 ram, loss 
of R wave in precordial eads) or by the elevation of 
creatine kinase MB levels to greater than 50 IU in the 
immediate 24-hour period after operation. Cardiac index 
was derived from thermodilution cardiac output measure- 
ments made hourly for 18 hours after operation. 
Inotropic agents were used to maintain a cardiac index 
of 2.0 L/min per square meter or higher and a systolic 
blood pressure of 90 mm Hg or higher after afterload, 
preload, and heart rate were maximized. In addition to 
reporting the actual incidence of use of inotropic agents, 
an inotropic score was also used to quantify the number of 
inotropes used, the dosage, and length of administration. 
The score ranged from 0 to 5 where 0 indicated no 
inotropes or dopamine 2 p~g/kg per minute or less, 1 
indicated inotropic support 2 txg/kg per minute or greater 
for 24 hours, 2 indicated use of two inotropes, 3 indicated 
use of epinephrine, 4 indicated use of three inotropes, and 
5 indicated inotropic support for 24 hours or more. 
Atrial pacing was instituted if the heart rate was 80 
beats/min or less with a cardiac index of 2.0 L/min per 
square meter or less. All patients were weighed the 
evening before operation and at 5 AM the day after 
operation to determine postoperative weight gain in 
pounds. The time spent on ventilator support was re- 
corded in hours from the time of admission to the ICU to 
the time of extubation. Standardized weaning protocols 
were used in all patients. Criteria for extubation in- 
cluded an inspiratory force of -<20 cm, a respiratory 
rate less than 30 breaths/min, oxygen saturation 90% or 
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greater, pH 7.35 to 7.45, and carbon dioxide tension less 
than 50 mm Hg. The incidence of atrial fibrillation was 
recorded for all patients along with the occurrence of 
ventricular arrhythmias. A documented ventricular ar- 
rhythmia consisted of either ventricular tachycardia or 
multifocal premature ventricular contractions necessi- 
tating drug therapy. Administration of/3-blockers was 
instituted before operation and on the first postopera- 
tive day in all patients with an ejection fraction of 40% 
or greater. 
Length of stay in the ICU was recorded for all patients. 
Before transfer from the ICU, patients had to be extu- 
bated and have stable vital signs without any inotropic 
support. Hospital length of stay was defined as the time in 
the hospital from the day of the operation to the day of 
discharge. Criteria for discharge included normal sinus 
rhythm, a temperature of less than 99 ° F, well-healed 
incisions, and the ability to walk and climb one flight of 
stairs with an oxygen saturation greater than 90% while 
breathing room air. 
Statistical analyses. Data are presented as the actual 
number of occurrences in a group and as the mean plus or 
minus the standard error. Analysis by X a test was used to 
compare occurrences between the GIK and no-GIK 
groups. Nonpaired Student's t tests were used to compare 
measured data between the groups. Data were considered 
significant at a p value of less than 0.05. 
Results 
Thirty-one patients were enrolled in the study. 
Sixteen patients were randomized to receive GIK 
solution. One patient was excluded from this group 
when the blood sugar value exceeded 325 mg/L 10 
hours into the infusion. The infusion was stopped 
and the blood sugar value decreased to 180 mg/L. 
This patient had an uncomplicated postoperative 
course. All 15 patients randomized to the no-GIK 
protocol completed the study. 
Patient profiles and cardiac risk factors. The 
mean age (GIK group: 60 years, range 50 to 80, vs 
no-GIK group: 65 years, range 39 to 83) and ratio of 
male to female patients (11/4 GIK vs 10/5 no-GIK 
group) were similar in both groups. All 30 patients 
received intravenous heparin treatment before CABG. 
A slightly higher percentage of patients in the GIK 
group received intravenous nitroglycerin therapy 
(12/15 vs 8/15) and had a prior myocardial infarction 
(14/15 vs 11/15). The incidence of congestive heart 
failure (4/15 GIK vs 3/15 no-GIK group), the need for 
preoperative IABP support (3/15 GIK vs 4/15 no-GIK 
group), and the mean ejection fraction (GIK: 43%, 
range 20% to 50%, vs no-GIK: 44%, range 30% to 
50%) were similar in the two groups. The majority of 
patients in both groups had hypertension (12/15 GIK 
vs 10/15 no-GIK group) whereas only a small percent- 
age had chronic obstructive pulmonary disease (3/15 
GIK vs 1/15 no-GIK group) or a previous cerebral 
vascular accident (1/15 GIK vs 2/15 no-GIK group). 
Operative results. There was no difference be- 
tween the groups in the duration of cardiopulmonary 
bypass (101.2 _+ 2.2 minutes GIKvs 98.6 _+ 6.1 minutes 
no-GIK group, p = 0.370) or the crossclamp time 
(43.8 _+ 2.6 minutes GIK vs 41.3 _+ 2.4 minutes 
no-GIK group; p = 0.240). The GIK group had a 
slightly higher number of vessels bypassed, which was 
nonetheless ignificant (3.46 _+ 0.16 vs 3.00 _+ 0.09;p = 
0.010; 95% confidence interval [CI] -0.86 to 0.07). 
Serum K + and glucose levels. Levels of serum 
K ÷ remained constant in both the GIK and no-GIK 
groups during the prebypass and reperfusion peri- 
ods (Fig. 1). 
There was no difference in serum glucose levels 
before the infusion of GIK solution (108 +_ 6 mg/L 
GIK vs 110 _+ 5 mg/L no-GIK group; p = 0.410) 
(Fig. 2). Glucose levels increased significantly before 
bypass in the GIK group and remained elevated 
during the infusion of the GIK solution in the 
reperfusion period (220 _+ 10 mg/L at 6 hours and 
240 _+ 10 mg/L at 12 hours). However, after the 
discontinuation of the GIK infusion, there was no 
difference in serum glucose level between the two 
groups (140 +_ 8 mg/L GIKvs 135 _ 5 mg/L no-GIK 
group at 18 hours of reperfusion; p = 0.350). 
Postoperative r sults. There were no deaths in 
either group. One patient in each group had a 
perioperative myocardial infarction. The postop- 
erative cardiac indices for both groups are sum- 
marized in Fig. 3. Although both groups started 
out with similar indices (GIK group: 2.1 _ 0.2 
L/min per square meter vs no-GIK group: 2.1 _+ 
0.2 L/min per square meter; p = 0.510) the 
patients treated with GIK solution had higher 
cardiac indices during reperfusion that persisted 
even after the GIK infusion was discontinued 
(GIK group: 2.8 _+ 0.1 L/min per square meter vs 
no-GIK group: 2.3 _+ 0.2 L/min per square meter; 
p < 0.001; 95% CI -1.20 to 0.312). Patients in the 
GIK group required less inotropic support (1/15 
vs 5/15; p = 0.080) and had significantly lower 
inotropic scores (0.06 _-2- 0.01 vs 0.46 _+ 0.19; p = 
0.041; 95% CI 0.31 to 3.81). They also required 
less atrial pacing (2/15 vs 10/15; p = 0.002). 
Patients treated with GIK solution gained less 
weight (GIK group: 6.4 _+ 0.9 pounds vs no-GIK 
group: 11.6 _+ 1.1 pounds;p < 0.001; 95% CI 2.08 
to 8.82) and had shorter times of ventilator sup- 
port (8.3 _+ 0.6 hours GIK vs 14.2 _+ 0.2 hours 
no-GIK group; p = 0.003; 95% CI 1.62 to 10.23). 
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Fig. 1. Serum K + levels. All values represent the mean plus or minus the standard error. Serum K + levels 
do not differ between the GIK and no-GIK groups. 
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Fig. 2. Serum glucose levels. All values represent the mean plus or minus the standard error. Serum 
glucose levels are higher in the GIK group during the infusion of GIK solution. After the discontinuation 
of GIK infusion, serum glucose level is not different from that in the no-GIK group. 
This contributed to a shorter length of stay in the 
ICU (14.8 + 1.3 hours G IK  vs 31.6 _ 5.2 hours 
no -G IK ;p  = 0.002; 95% CI 5.38 to 28.34. Patients 
who received G IK  solution also had a lower 
incidence of atrial fibrillation (2/15 vs 8/15; p = 
0.010) and ventricular arrhythmias (0/15 vs 3/15; 
p = 0.060). The shorter ICU stay and lower 
incidence of arrhythmia lso contributed to a signifi- 
cantly shorter hospital stay for patients in the GIK 
group (6.0 _+ 0.4 days GIK vs 8.0 _+ 0.7 days no-GIK 
group;p = 0.010; 95% CI 0.29 to 3.83). 
Discuss ion  
There are several mechanisms by which GIK 
solutions enhance the performance of the ischemic 
myocardium. The increased supply of adenosine 
triphosphate derived from glycolytic pathways plays 
an important role in maintaining cell membrane 
function and integrity, which is critical to the pres- 
ervation of myocytes and endothelial and vascular 
smooth muscle cells. 14 This limits cellular edema 
and microvascular compression, which contribute to 
the "no-reflow" phenomenon that may occur during 
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Fig. 3. Cardiac index (CI). All values represent the mean plus or minus the standard error. Cardiac index 
is significantly higher in the GIK group during reperfusion. 
reperfusion. Eberli and coworkers 15 were able to 
demonstrate increased blood flow and decreased 
coronary resistance during reperfusion i  ischemic 
hearts treated with GIK. This decrease in cellular 
edema may also have contributed to the decreased 
weight gain seen in the patients in our study who 
were treated with GIK solution. During ischemia, 
the accumulation f free fatty acid end products may 
impair ventricular function and increase the inci- 
dence of ventricular arrhythmia by increasing the 
level of oxygen-derived free radicals. 16 Glucose es- 
terifies intracellular f ee fatty acids by increasing the 
supply of oe-glycerophosphate, thereby decreasing 
the toxic metabolic end products of free fatty acids 
including oxygen-derived free radicals. 16'17 The 
beneficial effects of GIK solution on the ischemic 
myocardium are unlikely to be the result of its 
hyperosmolarity. In any experimental study with 
ischemic hypertrophied rat hearts, the substitution 
of mannitol for glucose failed to show the same 
degree of myocardial protection. 18
The superiority of glucose as a substrate in the 
ischemic myocardium has been documented in several 
clinical studies. In patients with coronary artery dis- 
ease, GIK therapy resulted in a more favorable oxygen 
supply/demand ratio by increasing arterial glucose 
uptake while decreasing free fatty acid levels. 19 Similar 
results were noted by Svedjeholm and colleagues 2°in 
patients receiving GIK infusions after elective CABG. 
Maki and associates 3 tudied the pattern of glucose 
utilization in patients with an occluded coronary artery 
and chronic wall motion abnormalities without a pre- 
vious infarction. Insulin infusions caused a striking 
increase in glucose uptake in both dysfunctional nd 
normal myocardial regions. These beneficial changes 
in myocardial metabolism were reflected in improved 
myocardial performance in patients after anterior 
myocardial infarcts, v'8 Patients treated with GIK infu- 
sions showed improved global ejection fraction values 
and significantly better egional wall motion in the 
infarcted area. Patients undergoing cardiac operation 
also appeared to benefit from treatment with GIK. 
Oldfield, Commerford, and Opie 9 treated patients 
with an infused GIK solution for 12 hours before a 
mitral valve replacement. These patients had a higher 
myocardial g ycogen content during the operation and 
had a lower incidence of postoperative arrhythmia 
than patients not treated with GIK. Coleman and 
coworkers 1° used GIK infusions in patients who re- 
quired IABP support o discontinue cardiopulmonary 
bypass after CABG. Although GIK did not alter 
mortality or infarction rates, the length of IABP sup- 
port and the need for inotropic agents were signifi- 
cantly decreased in the patients in the GIK-treated 
group. Girard and coworkers 11 noted higher cardiac 
indices in patients undergoing elective CABG who 
received pretreatment with GIK. 
One surprising finding in our study was the sig- 
nificant decrease in the incidence of atrial fibrilla- 
tion in the GIK group. The overall incidence of 
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atrial fibrillation in this study was 33%, which is 
similar to that in our previous eries and those of 
others. 2>24 Patients treated with GIK had only a 
13% incidence of atrial fibrillation compared with 
53% in patients in the no-GIK group. We and others 
have shown that postoperative atrial fibrillation in- 
creases length of hospital stay and can be associated 
with an increased incidence of strokes. 21' 22 There 
are several theories for the increased incidence of 
atrial arrhythmias after CABG. Kalman and co- 
workers 25 showed an increased incidence of higher 
postoperative norepinephrine levels in patients with 
atrial fibrillation undergoing CABG. This suggests 
that increased sympathetic activation may be an 
important mechanism for the development of atrial 
fibrillation. There is also evidence to suggest hat 
atrial ischemia during cardioplegic arrest may be an 
important factor. Tchervenkov and coworkers 23 
noted a strong correlation between the duration of 
atrial activity during cardioplegic arrest and the 
incidence of postoperative supraventricular ar hyth- 
mia in patients undergoing elective CABG. This 
suggests that atrial fibrillation may be a manifesta- 
tion of inadequate atrial protection during myocar- 
dial ischemia. Similar findings were also noted by 
Mullen 26 and Smith 27 and their associates who 
found that the atria in patients undergoing CABG 
with cold cardioplegic techniques were cooled less 
effectively than the ventricles. Cox 28 suggested that 
some patients are more vulnerable to postoperative 
atrial fibrillation because of a mild nonuniformity in 
the refractory period distribution in the atria of 
these patients. He believes that atrial ischemia s- 
sociated with rapid rewarming of the atria during 
cold cardioplegic arrest is more likely to result in 
atrial fibrillation in these patients. Pretreatment 
with GIK solution may increase myocardial glyco- 
gen stores and result in less atrial ischemia during 
cardioplegic arrest. Further evidence to support his 
theory comes from the work of Oldfield, Commer- 
ford, and Opie, 9 who biopsied the atria in patients 
who received GIK treatment 12 hours before mitral 
valve replacement. Patients treated with GIK had 
higher glycogen levels and a lower incidence of 
postoperative arrhythmia. 
One of the possible limitations of this study is that 
although the patients were prospectively random- 
ized, the staff caring for the patients knew which 
patients received GIK treatment. However, because 
the use of inotropic agents and the decisions to 
extubate the patients and discharge them from the 
ICU and hospital were all dictated by established 
protocols, it is unlikely that bias and selection 
influenced these results. 
GIK therapy was well tolerated and resulted in no 
adverse reactions. It is cheap, readily available from 
the hospital pharmacy, and easy to administer. To 
avoid the possibility of venous trauma caused by 
hyperosmolarity, GIK solution was only given 
through a central ine. Patients with diabetes were 
not included in this study but there is new evidence 
to suggest hat mortality in patients with diabetes 
who have acute myocardial infarctions can be signif- 
icantly reduced by the infusion of an insulin-glucose 
solution. 29 Future studies will be undertaken to 
determine whether GIK solution will be equally 
effective in reducing the morbidity and mortality of 
CABG in patients with diabetes. 
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Discussion 
Dr. Steven Guyton (Seattle, Wash.). GIK solutions have 
been around for quite some time. At the time of my work 
with George Clowes, the father of Alec Clowes, at the 
Sears Surgical Laboratory at Boston City Hospital he 
championed the improved myocardial performance with 
what he called "GKI" in patients with sepsis and other 
critically ill patients after operation. His work in substrate 
enhancement influenced the development of hyperali- 
mentation ow commonly used in our surgical ICUs. 
Perhaps we are now sophisticated nough in our methods 
of myocardial preservation and evaluation of myocardial 
performance that improvements with this sort of substrate 
enhancement will be measurable in clinical situations. I 
would like to be more clearly convinced. 
My greatest concerns with the mechanics of this study 
are the introduction of bias by the method of randomiza- 
tion, which I presume was done on the basis of even or 
odd clinic number, and the fact that the study was not 
blinded. In hindsight in my review of the manuscript i
seemed as though doing this as a blinded randomized trial 
would have been fairly easy to do. In the studies per- 
formed, as ! understand the randomization protocol, the 
patients would have been identified with the GIK group or 
the no-GIK group at the moment of presentation. 
The authors state that the patients in the GIK group 
required less inotropic support, yet GIK solutions them- 
selves enhance myocardial performance. Is GIK included 
in the inotropic score, or did the authors measure cate- 
cholamine levels in the GIK versus no-GIK groups? 
Dr. Lazar. Randomization was done by the last digit of 
the hospital number in those patients identified as being 
eligible for the study. We found it was difficult to do the 
study in a blinded fashion because the glucose levels were 
clearly elevated in patients in the GIK group. Although I 
share some of Dr. Guyton's concerns, I think this really 
did not influence the results. It is hard to see how the 
incidence of atrial fibrillation or ventricular arrhythmia 
would be affected. 
As far as the use of inotropes is concerned, the inotro- 
pic use in both groups was relatively small. We did not 
think of GIK solution as an inotrope. I think that the 
improvements seen in the cardiac index were the result of 
improved diastolic relaxation, better stroke work index, 
and overall general better ventricular performance in 
GIK-treated hearts. 
Dr. Guyton. The authors note a decrease in cellular 
edema as a potential mechanism for GIK. Because the 
solution is given systemically, is this lesser weight gain a 
myocardial phenomenon that we are seeing or is this a 
systemic effect with regard to the entire body? 
Dr. Lazar. This is most likely both a myocardial and 
systemic effect. 
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Dr. Guyton. This is an area of concern with regard to 
group bias, because the authors noted that there was 
less weight gain and less edema in the GIK group and 
that GIK in their evaluation limited fluid retention. Did 
they measure or record the amounts of fluid adminis- 
tration and urine output during the procedures and 
during the patient's hospital stay? What can they tell us 
about the fluid administration and management of both 
groups? 
Dr. Lazar. The fluid administration i  both groups was 
standardized through a standard postoperative protocol, 
so all these patients were weighed at 5 o'clock in the 
morning on the first postoperative day and we found as 
was the case in all our patients that the maximal weight 
gain was seen on that first postoperative day. We found no 
variations between the two groups as far as that was 
concerned. 
Dr. Guyton. Was more fluid administered to the GIK 
group? 
Dr. Lazar,. Yes, they received more fluid because a 
faster infusion rate was used in that group. 
Dr. Guyton. It would be of interest I think to look at a 
GIK group and a low-dose inotropically supported or 
routinely supported group to indicate the inotropic poten- 
tial of GIK solution. Perhaps now we are on the verge of 
seeing the marked improvements with substrate nhance- 
ment as we saw with hyperalimentation. 
Dr. Lazar. There are two reasons we would not do that 
particular study. First of all, low, dose inotropes are more 
expensive to use and, more important, what we found 
from this study is that the incidence of atrial arrhythmia 
was significantly decreased. At least in our own retrospec- 
tive series we found that the use of inotropes after 
operation was associated with a higher incidence of both 
atrial and ventricular arrhythmia, so I think that GIK is 
working not as an inotrope and I would think that the use 
of inotropes would have resulted in a higher incidence of 
arrhythmia. 
Dr. James Albert (Colorado Springs, Colo.). I was 
wondering whether the authors looked at the differences 
in urine output during the study period. I am concerned 
that because the glucose concentrations were significantly 
higher in the GIK group over a prolonged period, there 
may be a component of an osmotic diuresis that may be 
potentially responsible for the decreased weight gain in 
that group. 
Dr. Lazar. There is no question that there was some 
osmotic diuresis in the GIK group, but I do not think that 
was responsible for the beneficial results een in this study. 
Previous experimental studies in which mannitol was 
substituted for GIK failed to show the beneficial protec- 
tive effects on ventricular function. 
Dr. Albert. The second question I have is whether the 
authors were releasing the patients from the ICU in the 
middle of the night after procedures, because there was a 
significant difference in the ICU stay. In my experience 
patients operated on in both the morning and afternoon 
tend to be released the following morning if all goes well, 
which would result in a difference in the time in the ICU. 
Were there any differences in the times of day that the 
operations were done in both groups? 
Dr. Lazar. We did look at that and there were an equal 
number of afternoon and morning operations in both 
groups. The criteria for discharge from the ICU and 
discharge from the hospital are pretty rigid. The patients 
have to be receiving no inotropic support and be extu- 
bated to leave the ICU, and to leave the hospital they have 
to be afebrile with no active infections and be able to walk 
at least a certain distance with a certain acceptable oxygen 
saturation. 
Dr. Mark Metzdorff (Portland, Ore.). I am impressed by 
this carefully done study and intrigued by the salutary 
effects of this solution, especially as regards atrial fibrilla- 
tion, because that seems in our experience to be the 
primary cause of prolonged hospital stay. I think the 
authors rightly excluded some high-risk patients or some 
that would potentially confound the findings, such as 
those with diabetes and chronic renal failure, but in our 
practice that would account for about 40% of the patients 
we operate on. Do the authors anticipate xtending this 
treatment to these patients, or are they absolutely ex- 
cluded? 
Dr. Lazar. Such a protocol is going to be underway 
shortly with the help of our endocrinologists. I think the 
bigger issue that we are addressing is that those patients 
with ischemic heart disease do have an abnormality in the 
ability to use glucose and an abnormality in the ability 
to use insulin, and certainly the group that would tend 
to benefit the most are the patients with diabetes who 
tend to gain more weight, who have a higher incidence 
of perioperative infarcts, and in whom it is much more 
difficult to provide protection during the operation. 
Recent data in the cardiology literature show that 
similar GIK-type solutions have dramatically decreased 
the mortality from acute infarcts in patients with dia- 
betes, and we are actually now modifying the solution to 
use it in these patients. 
Dr. Philip Wright (Honolulu, Hawaii). This article 
seems to harken back to a period when potassium loading 
of patients after myocardial infarction was thought o be 
beneficial in reducing ventricular arrhythmia, s described 
by Dr. Sodi-Pollaris from Mexico City. I am wondering 
whether in a simplistic way the authors are telling us that 
potassium loading in these patients has some benefit 
inasmuch as I see the serum levels fluctuate very little. Is 
purely potassium loading independent of any other con- 
sideration providing the benefit in these patients? 
Dr. Lazar. I would think it is more the glucose than the 
potassium. I think the key element is getting substrate into 
the cells, especially in many of these patients who have 
ischemia before the operation. They are not infarcting, 
but they have underlying ischemia. ! think that surgeons 
were keying in on that period of ischemic arrest and 
reperfusion, and we really neglected that period before 
the patient gets to the operating room. 
Dr. Wright. My second question is that there has been 
some suggestion i  a paper presented earlier this week at 
the DeBakey Society of looking at insulin elaboration in 
various experimental preparations. There has been a 
suggestion that during bypass insulin elaboration by the 
pancreas may be at a reduced level or shut off, in which 
case adding insulin to this preparation is important. Do 
the authors have a comment? 
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Dr. Lazar. Yes, I agree with that wholeheartedly, and 
this gets back to the other question that was asked about 
the use of GIK solution in patients with diabetes. In 
preparation for the next protocol, we have actually initi- 
ated insulin drips in a number of our patients with 
diabetes rather than trying to give them spot doses of 
insulin as the glucose levels increase. We have seen a 
dramatic decrease in the weight gain in these patients, 
a decrease in the incidence of the use of inotropes, and 
a little bit faster extubation times. I think the other part 
of this whole process is the inability of the myocardium 
to adequately use insulin during the period of cardio- 
pulmonary bypass. It may be that bypass and ischemia 
act as a depressant and that the other important 
mechanism involved is the ability of endogenous or 
exogenous insulin to get more glucose into the cells. 
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